Fundraising Fox
/People
Sign in

David Grayzel

Investor

Managing Director at Atlas Venture · Board director at Xilio Therapeutics · Board director at Affinia Therapeutics

Cambridge, Massachusetts, United States

Writes $500K – $5M checks · typically $2M

Find your path to David

330 people in our graph can introduce you to David.

Each arrow is one introduction. Sign up to fill in the first one.

Ask Nessan Bermingham to introduce you to David

You →Nessan · together at Atlas Venture (2012–2020) →David

Ask Jamie Chen to introduce you to David

You →Jamie · 11 people · together at Atlas Venture →David

Sign up to find every way you can get introduced to David

  • Your email: the people you already email who know David
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with David
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

About

David Grayzel is a physician-turned-VC who repeatedly co-founds biotech companies and serves as CEO or chair, focusing on immune-system therapeutics in autoimmunity and oncology (Surface Oncology, Q32 Bio, Comanche Biopharma).

Contact· self-published, not guessed

Invests in

BiotechHealthtech

Board director at Xilio Therapeutics

Intro paths

→

In turn, David can intro founders to Xilio Therapeutics's investors below.

Xilio Therapeutics's investors · 16

AbingworthLondon · $15M – $30M checks · since 2020Atlas VentureCambridge · $500K – $1M checks · since 2021Bain Capitalsince 2021Bain Capital Life SciencesBoston · since 2021Bay City CapitalSan Rafael · $5M – $10M checksDeerfield Management CompanyNew YorkF-Prime CapitalCambridge · $3M – $10M checks · since 2021M VenturesLos Angeles · $10.8M checks · since 2020MRL Ventures FundCambridge · $25M checksRA CapitalBostonRiverVest Venture PartnersSt. Louis · $500K – $3M checksRock Springs CapitalBaltimoreSolasta VenturesBostonSV Health InvestorsLondon · $1M – $20M checks · since 2018SV7 Impact MedicineLondonTakeda VenturesCambridge · $1M – $5M checks

Co-founders at Xilio Therapeutics

RRRené Russo
René RussoExecutive Officer, Director

Board director at Affinia Therapeutics

Intro paths

→

In turn, David can intro founders to Affinia Therapeutics's investors below.

Affinia Therapeutics's investors · 8

Atlas VentureCambridge · $500K – $1M checks · since 2025EcoR1 CapitalSan FranciscoEight Roads VenturesMumbai · $5M – $30M checksF-Prime CapitalCambridge · $3M – $10M checks · since 2025GV (Google Ventures)Mountain View · $250K – $50M checksNEA SecondaryTimonium · since 2025New Enterprise Associates (NEA)Menlo Park · $200K – $40M checksTCG CrossoverPalo Alto

Co-founders at Affinia Therapeutics

LV
Luc VandenbergheDirector
ATAaron Tward, M.D., Ph.D.
Aaron Tward, M.D., Ph.D.Scientific Co-Founder
BRBotond Roska, M.D., Ph.D.
Botond Roska, M.D., Ph.D.Scientific Co-Founder
LV
Luk Vandenberghe, Ph.D.Scientific Co-Founder and Adviser, and Board Member

Experience

  1. Atlas VenturePartnercurrent2014 — presentCambridge, MA
  2. Atlas Venture Development Corp.Managing Directorcurrent2010 — present
  3. Infinity PharmaceuticalsVP Clinical Development and Medical Affairs2002 — 2010
  4. Dyax CorpDirector Corporate Development and Business Operations2000 — 2002
  5. Massachusetts General HospitalIntern, Resident1997 — 2000

Deals · 3

Xilio TherapeuticsBoard seat

via Atlas Venture · filed Feb 2021 · $95M raise

Aerovate Therapeutics, Inc.Board seat

via Atlas Venture · filed Aug 2020 · $75.8M raise

Akriveia TherapeuticsBoard seat

via Atlas Venture · filed Jan 2018 · $22.5M raise

Attribution from SEC filings, press coverage, and firm rosters.

Other disclosed investments

Board seats

AerovateAffinia TherapeuticsAffinia TherapeuticsAnnovation BiopharmaArteaus TherapeuticsCadent TherapeuticsComanche BiopharmaComanche BiopharmaDay One BiopharmaceuticalsDeliniaQ32 BioSurface OncologyTrace NeuroscienceTriana BioTRIANA BiomedicinesVima Therapeutics

Sources: the firm's website · SEC Form D filings · curated public sources.

Colleagues at Atlas Venture

Aimee Raleigh
Principal at Atlas Venture
Aimee Raleigh, PhD
Principal at Atlas Venture
Akshay Vaishnaw, MD, PhD
Venture Partner at Atlas Venture
Alex Harding, MD, MBA
Entrepreneur-in-Residence; Chief Executive Officer, Stealth NewCo at Atlas Venture
Alex Lugovskoy, PhD
Atlas Advisor; Chief Executive Officer, Diagonal Therapeutics at Atlas Venture
Alfica Sehgal, PhD
Entrepreneur-in-Residence; Chief Scientific Officer, Judo Bio at Atlas Venture
Andrea DiMella
Senior Vice President, Head of Talent at Atlas Venture
Angela Lam
Executive Assistant at Atlas Venture

Network5

Aimee Raleigh
Principal at Atlas Venture
Bruce Booth
Partner at Atlas Venture
Chelsea Johnson
Principal at Atlas Venture
Fred Destin
Founder at Stride VC
Jason Rhodes
Partner at Atlas Venture

Investors connected to David in public investor directories — a warm-intro map.

Frequently asked questions

Who is David Grayzel?
David Grayzel is a physician-turned-VC who repeatedly co-founds biotech companies and serves as CEO or chair, focusing on immune-system therapeutics in autoimmunity and oncology (Surface Oncology, Q32 Bio, Comanche Biopharma).
Where does David Grayzel work?
David Grayzel is Managing Director at Atlas Venture and Board director at Xilio Therapeutics and Board director at Affinia Therapeutics.
What does David Grayzel invest in?
David Grayzel invests in Biotech, Healthtech.
What check size does David Grayzel write?
David Grayzel typically writes checks of $500K – $5M.
What boards does David Grayzel sit on?
David Grayzel holds tracked board seats at Aerovate, Aerovate Therapeutics, Inc., Affinia Therapeutics, Affinia Therapeutics, Akriveia Therapeutics, Annovation Biopharma, Arteaus Therapeutics, Cadent Therapeutics, Comanche Biopharma, Comanche Biopharma.
What companies has David Grayzel invested in?
Investments tracked here include Affinia Therapeutics, Comanche Biopharma, Delinia, Q32 Bio, Trace Neuroscience, Triana Bio, Vima Therapeutics, Inc..
Where did David Grayzel go to school?
David Grayzel studied at Harvard Medical School (MD); Stanford University (BA).

Same school

Shared employers